Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/OARD1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/OARD1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/OARD1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/OARD1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/OARD1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
GO:19016574 | Esophagus | ESCC | glycosyl compound metabolic process | 57/8552 | 88/18723 | 2.32e-04 | 1.44e-03 | 57 |
GO:00091163 | Esophagus | ESCC | nucleoside metabolic process | 39/8552 | 62/18723 | 4.68e-03 | 1.82e-02 | 39 |
GO:007252112 | Liver | Cirrhotic | purine-containing compound metabolic process | 156/4634 | 416/18723 | 3.74e-09 | 1.52e-07 | 156 |
GO:19016572 | Liver | Cirrhotic | glycosyl compound metabolic process | 37/4634 | 88/18723 | 2.70e-04 | 2.40e-03 | 37 |
GO:0042278 | Liver | Cirrhotic | purine nucleoside metabolic process | 13/4634 | 26/18723 | 4.72e-03 | 2.48e-02 | 13 |
GO:0009116 | Liver | Cirrhotic | nucleoside metabolic process | 25/4634 | 62/18723 | 4.90e-03 | 2.56e-02 | 25 |
GO:007252122 | Liver | HCC | purine-containing compound metabolic process | 250/7958 | 416/18723 | 2.26e-13 | 1.24e-11 | 250 |
GO:19016571 | Liver | HCC | glycosyl compound metabolic process | 55/7958 | 88/18723 | 1.20e-04 | 1.01e-03 | 55 |
GO:00091161 | Liver | HCC | nucleoside metabolic process | 37/7958 | 62/18723 | 4.73e-03 | 2.02e-02 | 37 |
GO:19016573 | Oral cavity | OSCC | glycosyl compound metabolic process | 52/7305 | 88/18723 | 1.06e-04 | 7.84e-04 | 52 |
GO:007252120 | Oral cavity | OSCC | purine-containing compound metabolic process | 199/7305 | 416/18723 | 1.34e-04 | 9.53e-04 | 199 |
GO:00091162 | Oral cavity | OSCC | nucleoside metabolic process | 37/7305 | 62/18723 | 7.79e-04 | 4.23e-03 | 37 |
GO:190165711 | Oral cavity | LP | glycosyl compound metabolic process | 43/4623 | 88/18723 | 7.80e-07 | 2.05e-05 | 43 |
GO:000911611 | Oral cavity | LP | nucleoside metabolic process | 31/4623 | 62/18723 | 1.46e-05 | 2.57e-04 | 31 |
GO:0072521110 | Oral cavity | LP | purine-containing compound metabolic process | 130/4623 | 416/18723 | 1.30e-03 | 1.05e-02 | 130 |
GO:00422781 | Oral cavity | LP | purine nucleoside metabolic process | 14/4623 | 26/18723 | 1.33e-03 | 1.07e-02 | 14 |
GO:0072521112 | Skin | cSCC | purine-containing compound metabolic process | 150/4864 | 416/18723 | 2.88e-06 | 4.54e-05 | 150 |
GO:19016575 | Skin | cSCC | glycosyl compound metabolic process | 37/4864 | 88/18723 | 7.39e-04 | 5.15e-03 | 37 |
GO:00091164 | Skin | cSCC | nucleoside metabolic process | 27/4864 | 62/18723 | 1.99e-03 | 1.19e-02 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OARD1 | SNV | Missense_Mutation | rs770268622 | c.263C>T | p.Ser88Leu | p.S88L | Q9Y530 | protein_coding | tolerated(0.64) | benign(0.214) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OARD1 | SNV | Missense_Mutation | rs770268622 | c.263N>T | p.Ser88Leu | p.S88L | Q9Y530 | protein_coding | tolerated(0.64) | benign(0.214) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
OARD1 | SNV | Missense_Mutation | rs769331533 | c.376N>T | p.Arg126Cys | p.R126C | Q9Y530 | protein_coding | deleterious(0.01) | possibly_damaging(0.869) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
OARD1 | SNV | Missense_Mutation | rs769331533 | c.376C>T | p.Arg126Cys | p.R126C | Q9Y530 | protein_coding | deleterious(0.01) | possibly_damaging(0.869) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
OARD1 | SNV | Missense_Mutation | novel | c.343N>A | p.Leu115Ile | p.L115I | Q9Y530 | protein_coding | tolerated(0.69) | benign(0.012) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
OARD1 | SNV | Missense_Mutation | rs529411165 | c.409N>A | p.Glu137Lys | p.E137K | Q9Y530 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
OARD1 | SNV | Missense_Mutation | | c.445N>A | p.Val149Met | p.V149M | Q9Y530 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-AP-A0LP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Hormone Therapy | megace | SD |
OARD1 | SNV | Missense_Mutation | novel | c.150N>T | p.Lys50Asn | p.K50N | Q9Y530 | protein_coding | tolerated(0.24) | possibly_damaging(0.779) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
OARD1 | SNV | Missense_Mutation | rs529411165 | c.409N>A | p.Glu137Lys | p.E137K | Q9Y530 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
OARD1 | SNV | Missense_Mutation | novel | c.4N>A | p.Ala2Thr | p.A2T | Q9Y530 | protein_coding | tolerated_low_confidence(0.17) | benign(0) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |